Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort-Reference-Cited by-同舟云学术

Frequency and characteristics of infusion reactions during biosimilar infliximab treatment in inflammatory bowel diseases: results from Central European nationwide cohort

Published:2017-05-26 Issue:8 Volume:16 Page:885-890
ISSN:1474-0338
Container-title:Expert Opinion on Drug Safety
language:en
Short-container-title:Expert Opinion on Drug Safety

Author:

Bálint Anita¹,Rutka Mariann¹,Végh Zsuzsanna²,Kürti Zsuzsanna²,Gecse Krisztina B.²,Banai János³,Bene László⁴,Gasztonyi Beáta⁵,Kristóf Tünde⁶,Lakatos László⁷,Miheller Pál⁸,Palatka Károly⁹,Patai Árpád¹⁰,Salamon Ágnes¹¹,Szamosi Tamás³,Szepes Zoltán¹,Tóth Gábor Tamás¹²,Vincze Áron¹³,Bor Renáta¹,Milassin Ágnes¹,Fábián Anna¹^ORCID,Nagy Ferenc¹,Kolar Martin¹⁴¹⁵,Bortlik Martin¹⁴¹⁶,Duricova Dana¹⁴¹⁷,Hruba Veronika¹⁴,Lukas Martin¹⁴,Mitrova Katarina¹⁴¹⁸,Malickova Karin¹⁹,Lukas Milan¹⁴¹⁹,Lakatos Péter L.²,Molnár Tamás¹,Farkas Klaudia¹

Affiliation:

1. First Department of Medicine, University of Szeged, Szeged, Hungary

2. First Department of Internal Medicine, Semmelweis University, Budapest, Hungary

3. Military Hospital – State Health Centre, Budapest, Hungary

4. 1st Department of Medicine, Peterfy Hospital, Budapest, Hungary

5. 2nd Department of Medicine, Zala County Hospital, Zalaegerszeg, Hungary

6. 2nd Department of Medicine, B-A-Z County and University Teaching Hospital, Miskolc, Hungary

7. Department of Internal Medicine, Csolnoky Ferenc Regional Hospital, Veszprém, Hungary

8. Second Department of Internal Medicine, Semmelweis University, Budapest, Hungary

9. Institute of Medicine, Department of Gastroenterology, University of Debrecen, Clinical Center, Debrecen, Hungary

10. Department of Medicine and Gastroenterology, Markusovszky Hospital, Szombathely, Hungary

11. Department of Gastroenterology, Tolna County Teaching Hospital, Szekszárd, Hungary

12. Department of Gastroenterology, Janos Hospital, Budapest, Hungary

13. 1st Department of Medicine, University of Pécs, Pécs, Hungary

14. IBD Clinical and Research Centre, Iscarea.s., Prague, Czech Republic

15. 1st Medical Faculty, Charles University, Prague, Czech Republic

16. Department of Internal Medicine, Military Hospital, Charles University, Prague, Czech Republic

17. Institute of Pharmacology, 1st Medical Faculty, Charles University, Prague, Czech Republic

18. Department of Paediatrics, Faculty Hospital Motol, 2nd Medical Faculty, Charles University, Prague, Czech Republic

19. Institute of Medical Biochemistry and Laboratory Diagnostics, 1st Medical Faculty and General Teaching Hospital, Charles University, Prague, Czech Republic

Funder

Hungarian Academy of Sciences

New National Excellence Program of the Ministry of Human Capacities

research grant of the National Research, Development and Innovation Office

Publisher

Informa UK Limited

Subject

Pharmacology (medical),General Medicine

Link

https://www.tandfonline.com/doi/pdf/10.1080/14740338.2017.1323330

Reference22 articles.

2. Efficacy and safety of CT-P13, a biosimilar of infliximab, in patients with inflammatory bowel disease: A retrospective multicenter study